Vanderbilt Integrated Community TMS for Opioid Recovery
This study is looking at how a treatment called Repetitive Transcranial Magnetic Stimulation (rTMS) affects craving and opioid use in people with Opioid Use Disorder (OUD). rTMS uses magnetic pulses to stimulate a specific area of the brain. You might be able to join if you are 18-65 years old, have an OUD diagnosis, and have recently started buprenorphine but have also used opioids again. The researchers want to see if rTMS can reduce opioid craving, which is measured through self-reports and changes seen on an MRI scan. The study is planning to enroll 100 participants.
- Study design
- This study is an interventional study, meaning participants will receive a specific treatment. Participants will be randomly assigned to receive either active rTMS or a sham (inactive) rTMS, which looks and sounds the same but delivers no stimulation.
- What's involved
- You would attend 12 visits over about 5 months, with each visit lasting 1-2 hours. These visits will involve interviews, questionnaires, computer tasks, rTMS treatments, and optional MRI scans.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the start of the study (screening visit) up to a 20-week follow-up visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Vanderbilt Integrated Community TMS for Opioid Recovery
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Heather Ward, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Determining the effects of active left-DLPFC targeted iTBS compared to sham on craving and opioid use in 100 people with OUD through the Opioid Craving Scale.From the start of the study (screening visit) to the 20 week follow-up visit.
The primary outcome is to determine the effects of active left-DLPFC targeted iTBS compared to sham on craving in 100 people with OUD. Specifically, this study seeks to provide evidence that L DLFPC-targeted iTBS leads to reduced craving use in individuals with OUD. Participants' craving and drug use will be assessed prior to receiving iTBS, during iTBS intervention and following the end of iTBS (10, 12 and 20 weeks). Craving will be measured using the Visual Analogue Scale (VAS) on the Opioid Craving Scale (OCS).